Details

Autor(en) / Beteiligte

• Chmiel, Paulina
• Rutkowski, Piotr
• Spałek, Mateusz
• Szumera-Ciećkiewicz, Anna
• Czarnecka, Anna M.

Titel

What is the Optimal Treatment Strategy after Sarcoma R2 Surgery?

Ist Teil von

• Current treatment options in oncology, 2024-06, Vol.25 (6), p.798-812

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Opinion statement Soft tissue sarcomas (STS) are rare tumours of mesenchymal origin, most commonly occurring in the extremity but also in the retroperitoneum. The curative treatment for STS is radical surgery with wide margins, in some cases in combination with perioperative radiotherapy and chemotherapy. Nonradical resection (R2) of STS has been an emerging issue in recent decades, as optimal subsequent management remains debatable. Similarly, there is still no consensus on optimal surgical margins. Combining multiple treatment modalities in adjuvant therapy can achieve local and distant control in patients following surgery with positive margins. Patients who have undergone nonradical resection therefore require additional surgical interventions, and adjuvant radiotherapy resulting in a better prognosis but a higher number of complications. Following non-radical treatment, patients with limb and trunk wall sarcomas and retroperitoneal sarcomas should also undergo increased oncological surveillance. Given the potential issues that may emerge in such clinical situations, it is crucial to up-date the current guidelines to enhance the long-term prognosis of these patients.